Mei-Hsuan Lee1, Tiffany I Hsiao2,3, Shreenidhi R Subramaniam4, An K Le2, Vinh D Vu2, Huy N Trinh5, Jian Zhang6, Mingjuan Jin7, Vincent Wai-Sun Wong4, Grace Lai-Hung Wong4, Mindie H Nguyen2. 1. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 2. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA. 3. School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. 4. Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. 5. San Jose Gastroenterology, San Jose, Califonia, USA. 6. Chinese Hospital, San Francisco, Califonia, USA. 7. Department of Epidemiology and Biostatistics, School of Public Health, Zhejiang University, Hangzhou, China.
Abstract
OBJECTIVES: Hepatitis C virus (HCV) infection is a well-documented risk factor for hepatocellular carcinoma (HCC). Seven HCV genotypes have been classified, and the genotypes show a great variety of geographic distribution. HCV genotype 6 is prevalent in Southeast Asia and has been less studied than the other genotypes. METHODS: This follow-up study was designed to evaluate the natural history of HCV genotype 6. The cohort enrolled 851 Asian patients consisting of 222 with HCV genotype 6 and 629 with other genotypes. The incidence of HCC per 1,000 person-years of various HCV genotypes was estimated by dividing the new HCC cases to the person-years of follow-up. The adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox's proportional hazards models. RESULTS: After 4072 person-years of follow-up, there were 96 newly-developed HCC cases, confirming an incidence of 23.6 per 1000 person-years. By stratifying cirrhosis at study entry, the cumulative risk of HCC among HCV genotype 6 vs. non-6 was 2.9 vs. 2.2% for those without cirrhosis (P=0.45) and 76.2% (95% CI: 55.6-96.8%) vs. 36.2% (95% CI: 28.7-39.1%) for those with cirrhosis (P<0.05), respectively. Among patients with cirrhosis, HCV genotype 6 was significantly associated with HCC compared to patients with non-6 genotypes, with the adjusted HR=2.12 (1.33-3.39), P<0.05. In a model treating patients with genotypes other than 1 or 6 as the reference, the adjusted HR for HCC for HCV genotypes 1 and 6 were 1.13 (0.56-2.27) and 2.34 (1.12-4.86), respectively. CONCLUSIONS: Among patients with cirrhosis, those with HCV genotype 6 infection should be given high priority for antiviral therapy to decrease HCC risk and for vigilant adherence to HCC surveillance.
OBJECTIVES:Hepatitis C virus (HCV) infection is a well-documented risk factor for hepatocellular carcinoma (HCC). Seven HCV genotypes have been classified, and the genotypes show a great variety of geographic distribution. HCV genotype 6 is prevalent in Southeast Asia and has been less studied than the other genotypes. METHODS: This follow-up study was designed to evaluate the natural history of HCV genotype 6. The cohort enrolled 851 Asian patients consisting of 222 with HCV genotype 6 and 629 with other genotypes. The incidence of HCC per 1,000 person-years of various HCV genotypes was estimated by dividing the new HCC cases to the person-years of follow-up. The adjusted hazards ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox's proportional hazards models. RESULTS: After 4072 person-years of follow-up, there were 96 newly-developed HCC cases, confirming an incidence of 23.6 per 1000 person-years. By stratifying cirrhosis at study entry, the cumulative risk of HCC among HCV genotype 6 vs. non-6 was 2.9 vs. 2.2% for those without cirrhosis (P=0.45) and 76.2% (95% CI: 55.6-96.8%) vs. 36.2% (95% CI: 28.7-39.1%) for those with cirrhosis (P<0.05), respectively. Among patients with cirrhosis, HCV genotype 6 was significantly associated with HCC compared to patients with non-6 genotypes, with the adjusted HR=2.12 (1.33-3.39), P<0.05. In a model treating patients with genotypes other than 1 or 6 as the reference, the adjusted HR for HCC for HCV genotypes 1 and 6 were 1.13 (0.56-2.27) and 2.34 (1.12-4.86), respectively. CONCLUSIONS: Among patients with cirrhosis, those with HCV genotype 6 infection should be given high priority for antiviral therapy to decrease HCC risk and for vigilant adherence to HCC surveillance.
Authors: Nghia H Nguyen; Philip Vutien; Huy N Trinh; Ruel T Garcia; Long H Nguyen; Huy A Nguyen; Khanh K Nguyen; Mindie H Nguyen Journal: Hepatol Int Date: 2010-04-09 Impact factor: 6.047
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Kevin C Kin; Brian Lin; Kevin T Chaung; Nghiem B Ha; Huy N Trinh; Ruel T Garcia; Huy A Nguyen; Khanh K Nguyen; Brian S Levitt; Eduardo B da Silveira; Mindie H Nguyen Journal: Dig Dis Sci Date: 2013-10-01 Impact factor: 3.199
Authors: Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes Journal: Hepatology Date: 2014-07-28 Impact factor: 17.425
Authors: Mindie H Nguyen; Huy Trinh; Son Do; Thuan Nguyen; Pauline Nguyen; Linda Henry Journal: Am J Gastroenterol Date: 2017-10-31 Impact factor: 10.864
Authors: Phimpha Paboriboune; Thomas Vial; Philavanh Sitbounlang; Stéphane Bertani; Christian Trépo; Paul Dény; Francois-Xavier Babin; Nicolas Steenkeste; Pascal Pineau; Eric Deharo Journal: Virol Sin Date: 2018-06-13 Impact factor: 4.327
Authors: Cristina Maria Muzica; Carol Stanciu; Laura Huiban; Ana-Maria Singeap; Catalin Sfarti; Sebastian Zenovia; Camelia Cojocariu; Anca Trifan Journal: World J Gastroenterol Date: 2020-11-21 Impact factor: 5.742